RESUMO
C. difficile is a complication of antibiotic therapy. Certain antibiotics are associated with a higher rate of developing C. difficile. The charts of 54 patients with nosocomial C. difficile were reviewed and very few had received a high-risk antibiotic. Seven (13%) of 54 patients had not received any antibiotics in the hospital prior to the positive stool test for C. difficile. Moreover, 6 of the 7 had no documentation of receiving an antibiotic in the 56 days prior to admission suggesting that they might be colonized with C. difficile.
Assuntos
Antibacterianos/uso terapêutico , Clostridioides difficile/efeitos dos fármacos , Infecções por Clostridium/tratamento farmacológico , Infecção Hospitalar/tratamento farmacológico , Prescrição Inadequada/efeitos adversos , Pacientes Internados , Adulto , Idoso , Idoso de 80 Anos ou mais , Clostridioides difficile/isolamento & purificação , Infecções por Clostridium/diagnóstico , Infecções por Clostridium/epidemiologia , Infecção Hospitalar/microbiologia , Feminino , Hospitais , Humanos , Incidência , Pacientes Internados/estatística & dados numéricos , Tempo de Internação , Masculino , Testes de Sensibilidade Microbiana , Pessoa de Meia-Idade , Rhode Island/epidemiologiaAssuntos
Transtornos da Nutrição Infantil/fisiopatologia , Desidratação/fisiopatologia , Diarreia/fisiopatologia , Gastroenterite/fisiopatologia , Transtornos da Nutrição do Lactente/fisiopatologia , Bangladesh/epidemiologia , Transtornos da Nutrição Infantil/epidemiologia , Pré-Escolar , Estudos de Coortes , Comorbidade , Desidratação/diagnóstico , Desidratação/epidemiologia , Desidratação/terapia , Diarreia/epidemiologia , Diarreia/terapia , Feminino , Hidratação , Gastroenterite/epidemiologia , Gastroenterite/terapia , Frequência Cardíaca , Humanos , Lactente , Transtornos da Nutrição do Lactente/epidemiologia , Masculino , Mucosa , Estudos Prospectivos , Lágrimas , SedeRESUMO
INTRODUCTION: Previous studies of Ebola Virus Disease (EVD) have focused on clinical symptoms and Ebola virus (EBOV) cycle threshold (CT) values recorded at patient triage. Our study explores EVD symptoms and EBOV CT values from onset of illness to recovery or death in a diverse population of patients. METHODOLOGY/PRINCIPAL FINDINGS: We analyzed clinical care data from EBOV positive patients admitted to five Ebola treatment units in West Africa from 2014-2015. Prevalence of clinical signs/symptoms and CT values were explored using descriptive statistics. Logistic regression was used to examine their association with mortality. Survival was analyzed using Kaplan-Meier estimators from symptom onset date to death. During the first week of illness, dyspnea (OR = 2.44, 95% CI: 1.07-5.85) and tachycardia (OR = 10.22, 95% CI: 2.20-56.71) were associated with higher odds of mortality. Dyspnea (OR = 2.33, 95% CI: 1.210-4.581), bleeding (OR = 2.51, 95% CI: 1.219-5.337), and diarrhoea (OR = 2.79, 95% CI: 1.171-6.970) at any point during the illness course were associated with higher odds of mortality. Higher initial (OR = 0.85, 95% CI: 0.81-0.89) and mean (OR = 0.60, 95% CI: 0.53-0.66) CT values were associated with lower odds of mortality. CT values reached their nadir after 3-5 days of illness and then rose in both survivors and non-survivors until recovery or death. CONCLUSIONS/SIGNIFICANCE: Our study demonstrates the population prevalence of clinical signs/symptoms and EBOV CT values over time in a large, diverse cohort of patients with EVD, as well as associations between symptoms/EBOV CT values and mortality. These findings have implications on surveillance, operational planning, and clinical care for future EVD outbreaks.